Irbesartan (SR-47436) 是一种 Ang II 型 1 (AT1) 受体阻滞剂 (ARB)，具有口服活性。Irbesartan 可放松血管，降低血压，增加血液和氧气供应到心脏。 Irbesartan 可用于高血压、心力衰竭和糖尿病肾病的研究。
| 生物活性 | Irbesartan (SR-47436) is an orally activeAng II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1]. |
体外研究
(In Vitro) | Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro[1].
Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro[1].
Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro[1].
Cell Viability Assay[1] | Cell Line: | CD4+ T cells | | Concentration: | 0, 20, 40 and 60 μM | | Incubation Time: | 48 h | | Result: | Exerted no obvious effect on viability of CD4+T cells. |
|
体内研究
(In Vivo) | Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice[1].
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 50 mg/kg | | Administration: | oral gavage; 50 mg/kg/d; once daily | | Result: | Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.
Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.
Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis. |
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 20 μM | | Administration: | 20 μM; for 3 h | | Result: | Downregulated renal CCL20, CCL22 and CCL27 concentrations. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(233.36 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.3336 mL | 11.6678 mL | 23.3356 mL | | 5 mM | 0.4667 mL | 2.3336 mL | 4.6671 mL | | 10 mM | 0.2334 mL | 1.1668 mL | 2.3336 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.83 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com